甲基转移酶样因子14通路及其与接受结直肠癌手术患者病理分期的关系。
Methyltransferase-like factor 14 pathway and its relationship with pathological stages in patients undergoing surgery for colorectal cancer.
作者信息
Dai Qun, Ma Peng-Fei, Tian Jing, Zhang Zhan, Fang Qin, Lin Zi-Yu, Wu Li-Li, Li Xue-Min
机构信息
Department of Pathology, The Third People's Hospital of Hefei, Hefei Third Clinical College of Anhui Medical University, Hefei 230022, Anhui Province, China.
Department of Gastroenterology, Children's Hospital of Fudan University at Anhui, Anhui Provincial Children's Hospital, Hefei 230022, Anhui Province, China.
出版信息
World J Gastrointest Surg. 2025 May 27;17(5):101674. doi: 10.4240/wjgs.v17.i5.101674.
BACKGROUND
Epigenetic involvement of methyltransferase-like factor 14 (METTL14) in tumor development has not been clearly defined.
AIM
To investigate METTL14 expression and its relationship with pathological stage in patients undergoing radical surgery for colorectal cancer (CRC).
METHODS
This retrospective study included 80 patients with CRC who were admitted to the Third Hospital of Hefei and the Western District of the First Affiliated Hospital of Anhui Medical University between June 2021 and June 2024. These patients were selected for treatment. Lesions and adjacent tissues were collected from these patients, and METTL14 expression was assessed using immunohistochemistry. Expression levels of METTL14 were compared across different tissue samples. Additionally, we evaluated METTL14 expression in patients with varying pathological characteristics using statistical methods such as tests and analysis of variance to identify significant differences.
RESULTS
The positivity rate of METTL14 in tumor tissues was significantly lower than that in adjacent tissues (30% 60%, < 0.05). Conversely, the negative expression rate of METTL14 was higher in tumor tissues compared to adjacent tissues ( < 0.05). The positive expression of METTL14 mRNA did not differ by age, sex, tumor tissue classification, tumor diameter, or tumor location ( > 0.05). However, the positive expression rate of METTL14 was significantly lower in patients with lymph node metastasis, invasion depth T3 + T4, and tumor, node, and metastasis (TNM) stage III/IV compared to those without lymph node metastasis, invasion depth T1 + T2, and TNM stage I ( < 0.05). Specifically, METTL14 mRNA expression was significantly lower in patients with lymph node metastasis (0.51 ± 0.12 1.23 ± 0.25, < 0.001), invasion depth T3 + T4 (0.48 ± 0.15 1.18 ± 0.21, < 0.001), and TNM stage III/IV (0.45 ± 0.13 1.20 ± 0.22, < 0.001) compared to those with no lymph node metastasis, invasion depth T1 + T2, and TNM stage I, respectively.
CONCLUSION
In CRC, low positive METTL14 expression is closely correlated with lymph node metastasis, invasion depth T3 + T4, and TNM stage, indicating the malignant biological behavior of rectal cancer.
背景
甲基转移酶样因子14（METTL14）在肿瘤发生发展中的表观遗传作用尚未明确界定。
目的
探讨接受结直肠癌（CRC）根治性手术患者中METTL14的表达及其与病理分期的关系。
方法
本回顾性研究纳入了2021年6月至2024年6月期间在合肥市第三人民医院和安徽医科大学第一附属医院西区收治的80例CRC患者。选取这些患者进行治疗。收集这些患者的病变组织及邻近组织，采用免疫组织化学法评估METTL14的表达。比较不同组织样本中METTL14的表达水平。此外，我们使用检验和方差分析等统计方法评估不同病理特征患者中METTL14的表达，以确定显著差异。
结果
METTL14在肿瘤组织中的阳性率显著低于邻近组织（30%对60%，P<0.05）。相反，METTL14在肿瘤组织中的阴性表达率高于邻近组织（P<0.05）。METTL14 mRNA的阳性表达在年龄、性别、肿瘤组织分类、肿瘤直径或肿瘤位置方面无差异（P>0.05）。然而，与无淋巴结转移、浸润深度T1+T2和肿瘤、淋巴结、转移（TNM）分期I期的患者相比，有淋巴结转移、浸润深度T3+T4和TNM分期III/IV期的患者中METTL14的阳性表达率显著降低（P<0.05）。具体而言，与无淋巴结转移、浸润深度T1+T2和TNM分期I期的患者相比，有淋巴结转移的患者中METTL14 mRNA表达显著降低（0.51±0.12对1.23±0.25，P<0.001），浸润深度T3+T4的患者中METTL14 mRNA表达显著降低（0.48±0.15对1.18±0.21，P<0.001），TNM分期III/IV期的患者中METTL14 mRNA表达显著降低（0.45±0.13对1.20±0.22，P<0.001）。
结论
在CRC中，METTL14低阳性表达与淋巴结转移、浸润深度T3+T4和TNM分期密切相关，提示直肠癌的恶性生物学行为。
Zotero 插件